Precipio (PRPO) stock price is $22.13, down 4.82% on the day, as of Nov 13, 2026. It has a market cap of $39.68Mn, and is classified in the Diagnostic Labs industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap39.68 Mn
P/E-34.64
FCF (Yr)374,000.00
ROA (Yr)-1.89
EV to EBIT-18.73
Net Income (Yr)-363,000.00
Enterprise Value27.77 Mn
Add ratio to table…
About
Precipio, Inc. is a healthcare biotechnology company focused on improving cancer diagnostics, particularly hematologic malignancies, to address the systemic issue of disease misdiagnosis. The company operates at the intersection of clinical laboratory services and proprietary diagnostic product development, aiming to enhance diagnostic accuracy, accessibility, and workflow efficiency. Precipio’s integrated model leverages its pathology services to fund and accelerate…
Precipio, Inc. is a healthcare biotechnology company focused on improving cancer diagnostics, particularly hematologic malignancies, to address the systemic issue of disease misdiagnosis. The company operates at the intersection of clinical laboratory services and proprietary diagnostic product development, aiming to enhance diagnostic accuracy, accessibility, and workflow efficiency. Precipio’s integrated model leverages its pathology services to fund and accelerate research and development, creating a self-sustaining cycle of innovation and commercialization in oncology diagnostics.
Precipio generates revenue through two primary channels: diagnostic testing services and the sale of proprietary diagnostic products. The pathology services division provides specialized cancer diagnostic testing, including molecular diagnostics and cytogenetics, to physicians, hospitals, and laboratories, with reimbursement primarily from Medicare, Medicaid, and private insurers. The products division commercializes proprietary assays and diagnostic kits, such as HemeScreen and IV-Cell, which are sold to clinical laboratories to improve testing accuracy and operational efficiency. Revenue from products offers scalability, though adoption depends on regulatory approvals, reimbursement policies, and market demand.
The company operates through the following divisions:
Pathology Services Division: This division delivers specialized diagnostic testing for hematologic cancers, including molecular diagnostics, cytogenetics, and advanced laboratory analyses. It operates two full-service laboratories equipped to process patient samples daily, providing pathology reports to healthcare providers. The division serves as an internal clinical environment for developing, testing, and validating new diagnostic products while generating recurring service revenue. It also facilitates direct engagement with clinicians and access to patient samples, which informs product development.
Products Division: This division focuses on developing and commercializing proprietary diagnostic assays and kits designed for use by external clinical laboratories. Key activities include assay development, validation, manufacturing, and distribution through laboratory partners and commercial channels. The division’s offerings, such as HemeScreen and IV-Cell, aim to improve laboratory workflow efficiency, reduce testing turnaround times, and lower operational costs for customers. Product revenues are scalable but subject to regulatory and market adoption risks.
Precipio occupies a distinctive position within the oncology diagnostics industry by combining clinical laboratory operations with product development. Its integrated model provides a competitive edge, enabling rapid and cost-efficient innovation through direct access to patient samples, clinical feedback, and operational infrastructure. Key competitors in pathology services include NeoGenomics Laboratories, GenPath Diagnostics, LabCorp, and Quest Diagnostics, while product competitors range from reagent manufacturers like Qiagen and BioRad to next-generation sequencing providers such as Illumina and Roche. Precipio’s advantages stem from its ability to develop clinically relevant, workflow-optimized solutions that address gaps in diagnostic accuracy and laboratory economics, positioning it as a niche player with potential for broader market adoption.
Precipio serves a diverse customer base, including physicians, hospitals, clinical laboratories, and oncology practices across over 20 U. S. states. Its pathology services division primarily caters to healthcare providers requiring specialized cancer diagnostics, while the products division targets clinical laboratories seeking cost-effective, efficient diagnostic tools. The company’s technologies, such as HemeScreen and IV-Cell, are designed to improve diagnostic precision and reduce misdiagnosis rates, appealing to institutions focused on value-based care and operational efficiency.
Sector:HealthcareSector rationalePrecipio operates as a healthcare biotechnology company providing both diagnostic testing services (Pathology Services Division) and proprietary diagnostic products like HemeScreen and IV-Cell (Products Division). Both business lines fall squarely within the Healthcare sector, specifically under Diagnostic Labs and Medical Devices/Life Sciences Tools.Industries:Diagnostic LabsDiagnostic LabsPrimaryPrecipio operates two full-service laboratories that provide specialized cancer diagnostic testing, including molecular diagnostics and cytogenetics, to physicians and hospitals. This division generates recurring service revenue reimbursed by Medicare, Medicaid, and private insurers.Diagnostic EquipmentDiagnostic EquipmentSecondaryThe company's Products Division commercializes proprietary diagnostic assays and kits, such as HemeScreen and IV-Cell, which are sold as products to external clinical laboratories.Classified using BQ-MICSCIK: 0001043961
Bull & bear
Investment Thesis
▲ Bull case
Precipio's proprietary product pipeline represents a significant and underappreciated growth engine, with the commercial team adding approximately $3 million in annualized revenue potential during Q1 2026 alone, bringing the total pipeline to $10 million in annualized revenue potential. This pipeline growth occurred despite only partial quarters of effort from the newly hired commercial team, who spent substantial time on training and relationship-building, suggesting that the current pipeline figure is conservative and understates the true near-term conversion potential. The company's disciplined lead qualification process—requiring existing cancer diagnostic operations and measurable testing volumes—ensures that these opportunities are grounded in real commercial demand rather than speculative outreach. Given the historical conversion rates implied by early traction and the structural shift toward recurring revenue from product sales, the market is likely underestimating the speed at which this pipeline will convert to booked revenue, particularly as distributor relationships mature and sales cycles shorten through process refinement.
The pathology services business, often viewed as a low-growth legacy segment, possesses substantial untapped capacity that could drive meaningful margin expansion without significant new capital investment. Precipio operates its Connecticut laboratory at approximately $24 million in annualized revenue but has between $45 million to $50 million of utilizable capacity before requiring material CapEx or hiring increases. This implies nearly 100% of additional revenue from existing infrastructure could flow directly to the bottom line as gross profit, creating powerful operational leverage. With reimbursement headwinds from the CMS fee schedule being temporary and isolated to specific test codes (such as the 8% reduction in flow cytometry), and with the company actively mitigating impact through cost controls and operational efficiency, the pathology segment is positioned to generate steadily increasing cash flow as volume normalizes and reimbursement volatility subsides. This stable, cash-generative foundation is being underpriced by the market, which focuses excessively on short-term earnings swings while ignoring the inherent scalability of the core lab asset.
Precipio's business model—integrating a CLIA-certified clinical laboratory with product development and commercialization—creates a structural advantage that reduces development risk and accelerates time-to-market for new diagnostics, a factor not fully appreciated by investors focused solely on near-term revenue fluctuations. By validating products in its own lab under real-world conditions, the company avoids the lengthy and costly validation cycles typical of traditional diagnostic developers, enabling faster iteration and lower R&D intensity when expanding into adjacent markets. Management emphasized that this model allows for capital-efficient entry into new diagnostic areas (e.g., solid tumors or immunotherapy response monitoring) without the need for large-scale, upfront R&D spending, leveraging instead existing infrastructure and clinical workflow expertise. As the company scales its product revenue and strengthens cash flow, it will be increasingly well-positioned to pursue these adjacent opportunities with minimal dilution or debt, representing a long-term optionality that is not reflected in current valuations.
Precipio's proprietary product pipeline represents a significant and underappreciated growth engine, with the commercial team adding approximately $3 million in annualized revenue potential during Q1 2026 alone, bringing the total pipeline to $10 million in annualized revenue potential. This pipeline growth occurred despite only partial quarters of effort from the newly hired commercial team, who spent substantial time on training and relationship-building, suggesting that the current pipeline figure is conservative and understates the true near-term conversion potential. The company's disciplined lead qualification process—requiring existing cancer diagnostic operations and measurable testing volumes—ensures that these opportunities are grounded in real commercial demand rather than speculative outreach. Given the historical conversion rates implied by early traction and the structural shift toward recurring revenue from product sales, the market is likely underestimating the speed at which this pipeline will convert to booked revenue, particularly as distributor relationships mature and sales cycles shorten through process refinement.
The pathology services business, often viewed as a low-growth legacy segment, possesses substantial untapped capacity that could drive meaningful margin expansion without significant new capital investment. Precipio operates its Connecticut laboratory at approximately $24 million in annualized revenue but has between $45 million to $50 million of utilizable capacity before requiring material CapEx or hiring increases. This implies nearly 100% of additional revenue from existing infrastructure could flow directly to the bottom line as gross profit, creating powerful operational leverage. With reimbursement headwinds from the CMS fee schedule being temporary and isolated to specific test codes (such as the 8% reduction in flow cytometry), and with the company actively mitigating impact through cost controls and operational efficiency, the pathology segment is positioned to generate steadily increasing cash flow as volume normalizes and reimbursement volatility subsides. This stable, cash-generative foundation is being underpriced by the market, which focuses excessively on short-term earnings swings while ignoring the inherent scalability of the core lab asset.
Precipio's business model—integrating a CLIA-certified clinical laboratory with product development and commercialization—creates a structural advantage that reduces development risk and accelerates time-to-market for new diagnostics, a factor not fully appreciated by investors focused solely on near-term revenue fluctuations. By validating products in its own lab under real-world conditions, the company avoids the lengthy and costly validation cycles typical of traditional diagnostic developers, enabling faster iteration and lower R&D intensity when expanding into adjacent markets. Management emphasized that this model allows for capital-efficient entry into new diagnostic areas (e.g., solid tumors or immunotherapy response monitoring) without the need for large-scale, upfront R&D spending, leveraging instead existing infrastructure and clinical workflow expertise. As the company scales its product revenue and strengthens cash flow, it will be increasingly well-positioned to pursue these adjacent opportunities with minimal dilution or debt, representing a long-term optionality that is not reflected in current valuations.
Precipio remains highly vulnerable to external reimbursement decisions beyond its control, as demonstrated by the 8% CMS fee schedule reduction in Q1 2026 that directly reduced gross profit by approximately $125,000 and swung adjusted EBITDA from positive to negative despite underlying business stability. The company's pathology services—which still constitute over 89% of total revenue—are subject to annual, non-negotiable federal pricing updates that consistently trend downward or flat, with no ability to pass through cost increases or negotiate rates. This structural dependence on CMS creates persistent revenue volatility that cannot be fully mitigated through internal efficiency gains alone, especially as the company continues to rely on legacy test panels that are increasingly subject to commoditization and rate pressure. The market may be underestimating the cumulative impact of these annual reimbursement cuts, which could steadily erode pathology margins over time and divert cash flow from growth investments toward mere maintenance of profitability.
The products business, while positioned as the primary growth driver, continues to face prolonged and unpredictable sales cycles due to non-technical barriers in customer onboarding, such as physician training scheduling and institutional approval processes, which are entirely outside Precipio's control and can delay revenue recognition by multiple quarters. As illustrated by the CEO's example of a validated customer awaiting a quarterly physician education meeting, even technically ready accounts face delays rooted in healthcare organizational inertia, making revenue forecasting highly uncertain and increasing the risk that pipeline conversion lags significantly behind management's expectations. With the commercial team only recently hired and still in early stages of execution, there is a material risk that the $10 million annualized pipeline will convert to revenue much slower than anticipated, leaving the company dependent on the stagnant or declining pathology segment for longer than modeled, thereby delaying the anticipated inflection point in margin expansion and cash flow generation.
Despite repeated emphasis on operational leverage and margin improvement as product revenue scales, Precipio has yet to demonstrate sustained profitability or positive adjusted EBITDA on a run-rate basis, with Q1 2026 adjusted EBITDA at negative $200,000 following a strong Q4 2025 performance that was inflated by nonrecurring items. The company's gross margin declined to 40% in Q1 from 47% in Q4, and while management attributes this to temporary factors, the persistence of reimbursement headwinds, product revenue timing shifts, and ongoing commercial investments raises concerns about whether the underlying business can achieve meaningful scale without continuous external funding. Given the limited scale of the current products business—generating just under $3 million annually—and the long historical timeline required to penetrate diagnostic markets, there is a tangible risk that revenue growth fails to outpace operating expenses, resulting in a prolonged period of negative or break-even earnings that could necessitate dilutive financing or force a strategic retreat from growth initiatives.
Precipio remains highly vulnerable to external reimbursement decisions beyond its control, as demonstrated by the 8% CMS fee schedule reduction in Q1 2026 that directly reduced gross profit by approximately $125,000 and swung adjusted EBITDA from positive to negative despite underlying business stability. The company's pathology services—which still constitute over 89% of total revenue—are subject to annual, non-negotiable federal pricing updates that consistently trend downward or flat, with no ability to pass through cost increases or negotiate rates. This structural dependence on CMS creates persistent revenue volatility that cannot be fully mitigated through internal efficiency gains alone, especially as the company continues to rely on legacy test panels that are increasingly subject to commoditization and rate pressure. The market may be underestimating the cumulative impact of these annual reimbursement cuts, which could steadily erode pathology margins over time and divert cash flow from growth investments toward mere maintenance of profitability.
The products business, while positioned as the primary growth driver, continues to face prolonged and unpredictable sales cycles due to non-technical barriers in customer onboarding, such as physician training scheduling and institutional approval processes, which are entirely outside Precipio's control and can delay revenue recognition by multiple quarters. As illustrated by the CEO's example of a validated customer awaiting a quarterly physician education meeting, even technically ready accounts face delays rooted in healthcare organizational inertia, making revenue forecasting highly uncertain and increasing the risk that pipeline conversion lags significantly behind management's expectations. With the commercial team only recently hired and still in early stages of execution, there is a material risk that the $10 million annualized pipeline will convert to revenue much slower than anticipated, leaving the company dependent on the stagnant or declining pathology segment for longer than modeled, thereby delaying the anticipated inflection point in margin expansion and cash flow generation.
Despite repeated emphasis on operational leverage and margin improvement as product revenue scales, Precipio has yet to demonstrate sustained profitability or positive adjusted EBITDA on a run-rate basis, with Q1 2026 adjusted EBITDA at negative $200,000 following a strong Q4 2025 performance that was inflated by nonrecurring items. The company's gross margin declined to 40% in Q1 from 47% in Q4, and while management attributes this to temporary factors, the persistence of reimbursement headwinds, product revenue timing shifts, and ongoing commercial investments raises concerns about whether the underlying business can achieve meaningful scale without continuous external funding. Given the limited scale of the current products business—generating just under $3 million annually—and the long historical timeline required to penetrate diagnostic markets, there is a tangible risk that revenue growth fails to outpace operating expenses, resulting in a prolonged period of negative or break-even earnings that could necessitate dilutive financing or force a strategic retreat from growth initiatives.